ARM Stock Today: March 25 – AGI CPU Debut, Meta Deal Lift Outlook

The arm share price surged today after Cambridge-based ARM announced its first in‑house Arm AGI CPU for data centres and named Meta as a lead co-development partner. Investors are reading this as a shift from pure IP licensing to selective silicon sales, which could widen revenue streams. With demand for AI data centre chips rising across hyperscalers and enterprises, the market is betting on new design wins and early OEM availability. We break down what changed, how the stock reacted, and what UK investors should watch next.

AGI CPU launch and Meta partnership

Arm introduced the Arm AGI CPU, positioning it as a server-class processor aimed at agentic AI workloads and rack-level efficiency. The company highlighted performance-per-watt and software compatibility across its ecosystem. Management framed this as the silicon foundation for AI-scale cloud computing. Details and positioning are in Arm’s blog post: Announcing Arm AGI CPU. Early OEM availability is flagged, which supports near-term evaluation cycles.

Meta is a named co-development partner, validating the roadmap and potentially accelerating adoption. This signals traction with a top-tier hyperscaler, which could spur broader ecosystem interest. While commercial terms were not disclosed, the collaboration strengthens confidence in deployment pathways. Meta outlined the partnership here: Meta Partners With Arm. Momentum like this often supports the arm share price as investors price in future design wins.

Market reaction and valuation check

The arm share price jumped 16.38% to $157.07, with an intraday range of $148.25 to $166.69. It now sits 36.90% higher year to date and 26.38% over 12 months, versus a 52-week high of $183.16. Technicals are stretched, with RSI at 77.53 and price breaking above prior bands, signalling overbought conditions and elevated volatility.

Expect rich multiples to persist while growth is front-loaded. Price-to-sales is about 30.46, and profitability remains healthy with a 17.15% net margin and 11.03% ROE. Next earnings are scheduled for 6 May 2026. Street stance leans positive, with 14 Buy, 3 Hold, and 1 Sell ratings. These support sentiment around the arm share price, but execution must follow.

Business model shift and revenue optionality

Arm’s selective move into silicon could add high-value revenue streams beyond royalties. Selling chips introduces inventory and support requirements, but it also deepens customer ties and pricing power. R&D intensity is high at 56.26% of revenue, so scale matters. If OEM uptake is solid, blended margins could improve over time, which would underpin the arm share price.

AI infrastructure spend is expanding as enterprises standardise on efficient compute. Arm’s pitch targets better performance-per-watt at rack level, which resonates with power-constrained data halls. Success hinges on software readiness, OEM design wins, and hyperscaler trials. Clear roadmaps for inference and agentic workloads will shape adoption. This is where interest in AI data center chips is rapidly concentrating.

What UK investors should watch next

Track OEM announcements, benchmark disclosures, and hyperscaler pilots through 2026. Early availability talk is positive, but proof comes from purchase orders and multi-generation roadmaps. For UK investors, remember the ADR trades in New York, so news may hit after London hours. Sustained partner expansion beyond Meta would strengthen conviction.

Rival server CPUs and accelerators remain fierce competition. Pricing, supply chain execution, and software optimisation are ongoing risks. A hot technical setup, with RSI in overbought territory, adds near-term pullback risk. Watch the May earnings update for revenue guidance, design-win colour, and capex needs. Any slip could pressure the arm share price even if the long-term story stays intact.

Final Thoughts

Arm’s AGI CPU announcement and the Meta partnership improve line of sight to data centre wins, while signalling a careful expansion beyond licensing. The arm share price reaction reflects stronger expectations for revenue diversity and ecosystem reach. From here, we would track three items closely: first OEM design wins and benchmarks, then hyperscaler pilots, and finally revenue cadence in the May update. Valuation is demanding and technicals are hot, so entries may benefit from patience and position sizing. Long-only investors might scale in on weakness, while traders should respect volatility and defined risk. As always, this is information, not advice.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.